Contemporary developments in the discovery of selective factor Xa inhibitors: A review.
Thrombosis is a leading cause of death in cardiovascular diseases such as myocardial infarction (MI), unstable angina and acute coronary syndrome (ACS) in the industrialized world. Venous thromboembolism is observed in about 1 million people every year in United States causing significant morbidity and mortality. Conventional antithrombotic therapy has been reported to have several disadvantages and limitations like inconvenience in oral administration, bleeding risks (heparin analogs), narrow therapeutic window and undesirable interactions with food and drugs (vitamin K antagonist-warfarin). The unmet medical demand for orally active safe anticoagulants has generated widespread interest among the medicinal chemists engaged in this field. To modulate blood coagulation, various enzymes involved in the coagulation process have received great attention as potential targets by various research groups for the development of oral anticoagulants. Among these enzymes, factor Xa (FXa) has remained the centre of attention in the last decade. Intensive research efforts have been made by various research groups for the development of small, safe and orally bioavailable FXa inhibitors. This review is an attempt to compile the research work of various researchers in the direction of development of FXa inhibitors reported since 2010 onward.
Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda, Vadodara 390001, Gujarat, India.
Nirav R
NR
Patel
Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda, Vadodara 390001, Gujarat, India.
Dushyant V
DV
Patel
Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda, Vadodara 390001, Gujarat, India.
Prashant R
PR
Murumkar
Faculty of Pharmacy, Kalabhavan Campus, The Maharaja Sayajirao University of Baroda, Vadodara 390001, Gujarat, India. Electronic address: mryadav11@yahoo.co.in.
Mange Ram
MR
Yadav
D055808:Drug Discovery / Q000379:methods*; D065427:Factor Xa Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D009930:Organic Chemicals / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship
D065427:Factor Xa Inhibitors; D009930:Organic Chemicals
FXa inhibitors; Factor Xa; Thrombosis